Therefore, pharmacological cotargeting of both the de novo and salvage biosynthetic pathways, thanks to the new dCK inhibitor OR0642, is well tolerated and highly effective against T-ALL leukemic cells in vivo. The gene discussed is DCK; the disease is acute lymphoblastic leukemia.